IDEXX LABORATORIES INC /DE — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-02-17

Reporting Person: MAZELSKY JONATHAN JAY (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-17	Common Stock	M	25000	$52	Acquired	68090	Direct
2021-02-17	Common Stock	S	3940	$535.9391	Disposed	64150	Direct
2021-02-17	Common Stock	S	5376	$536.7803	Disposed	58744	Direct
2021-02-17	Common Stock	S	3069	$537.8393	Disposed	55705	Direct
2021-02-17	Common Stock	S	500	$538.83	Disposed	55205	Direct
2021-02-17	Common Stock	S	300	$540.8226	Disposed	54905	Direct
2021-02-17	Common Stock	S	583	$542.0814	Disposed	54322	Direct
2021-02-17	Common Stock	S	100	$543.14	Disposed	54222	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-17	Non-Qualified Stock Option (right-to-buy)	$52	M	25000	Disposed	2023-12-04	Common Stock (25000)	Direct

Footnotes

F1: Represents the weighted average price of the shares sold ranging from a low of $535.325 to a high of $536.28 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F2: Represents the weighted average price of the shares sold ranging from a low of $536.33 to a high of $537.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $537.388 to a high of $538.12 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $540.218 to a high of $541.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Represents the weighted average price of the shares sold ranging from a low of $542.08 to a high of $542.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F6: Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F7: Not applicable.